Incyte Corp Stock Price, News & Analysis

Incyte (Nasdaq: INCY) has announced its upcoming participation at the Goldman Sachs Healthcare Conference. The presentation is scheduled for Monday, June 9, 2025 at 11:20 am ET. Investors and interested parties can access the live webcast through Investor.Incyte.com, with the replay remaining available for 30 days following the presentation.

Incyte reports strong Q1 2025 financial results with total revenues reaching $1.05 billion, up 20% year-over-year. The company's flagship drug Jakafi achieved net product revenues of $709 million (+24% Y/Y), leading to increased 2025 guidance of $2.95-3.0 billion.

Key highlights: - Total product revenues: $922 million (+26% Y/Y) - Opzelura cream revenues: $119 million (+38% Y/Y) - New drug Niktimvo: $14 million in first two months of launch

Pipeline developments show promising results for povorcitinib in both hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The company continues advancing its innovative pipeline across multiple indications, including myeloproliferative neoplasms, GVHD, and various inflammatory conditions. Financial performance shows strong GAAP net income of $158.2 million with diluted EPS of $0.80.

Incyte (NASDAQ:INCY) has announced plans to present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago from April 25-30. The presentations will showcase research across multiple programs, including treatments for myeloproliferative neoplasms, ovarian cancer, and other solid tumors.

Key presentations include data on INCB177054, a novel DGKα/ζ dual inhibitor; INCA33890, a bispecific antibody targeting PD-1 and TGFβR2; and INCB057643, a BET protein inhibitor showing improvements in bone marrow function and effects on myelofibrosis treatment. The research demonstrates Incyte's ongoing efforts to advance its pipeline and transform cancer treatment approaches.

Incyte (NASDAQ: INCY) has announced the presentation of multiple abstracts featuring new data from its oncology portfolio at the 2025 ASCO Annual Meeting (May 30 – June 3, 2025) in Chicago.

The presentations will showcase data from both approved medicines and early-stage pipeline, including:

• Phase 1 study results of INCB123667, a selective CDK2 inhibitor, for advanced platinum-resistant ovarian cancer
• Phase 2 study results of pemigatinib for pre-treated glioblastoma with FGFR1-3 alterations
• Multiple studies on retifanlimab in treating various cancers including anal canal carcinoma and Merkel cell carcinoma
• Data on INCB057643, a BET inhibitor, for myelofibrosis treatment

Incyte (Nasdaq: INCY) has scheduled its first quarter 2025 financial results announcement for April 29, 2025. The company will release its Q1 2025 financial results via press release at 7:00 a.m. ET, followed by a conference call and webcast at 8:00 a.m. ET.

Investors can access the conference call through domestic (877-407-3042) and international (201-389-0864) dial-in numbers using conference ID 13753168. A replay will be available for 30 days, and the webcast with slides can be accessed at Investor.Incyte.com, remaining available for 90 days.

Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 24 new employees, totaling 20,334 shares of company common stock. The grants were made under the company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for April 1, 2025.

The awards were approved by the compensation committee of Incyte's board of directors as an inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting annually, contingent upon continued employment.